Zhiyuan Yao , Tong Qiu , Changlei Li , Weimao Kong , Guangqi Li , Peng Song , Guohua Wang , Wenjie Jiao
{"title":"Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases","authors":"Zhiyuan Yao , Tong Qiu , Changlei Li , Weimao Kong , Guangqi Li , Peng Song , Guohua Wang , Wenjie Jiao","doi":"10.1016/j.lungcan.2025.108414","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Primary pulmonary adenoid cystic carcinoma (PACC) is a rare malignant tumor. Despite the growing sophistication of ACC research, scant studies have delved into the unique molecular alterations of ACC originating from the lung and the clinical features associations.</div></div><div><h3>Method</h3><div>Paraffin-embedded specimens of primary PACC tissues pathologically confirmed at the Affiliated Hospital of Qingdao University within the past decade were collected. We comprehensively evaluated the diversity of molecular alterations in PACC using immunohistochemistry (IHC) staining, fluorescence <em>in-situ</em> hybridization (FISH), and next-generation sequencing (NGS). Furthermore, the potential correlations between MYB rearrangement status and clinicopathological features were thoroughly analyzed.</div></div><div><h3>Result</h3><div>Twenty-one specimens of primary PACC were collected, including eighteen of the typical type and three of the solid-basaloid type. Fifteen (71.4 %) specimens exhibited positive MYB staining and MYB rearrangements. Notably, neither clinicopathological parameters nor MYB rearrangement predicted patients’ overall survival (OS). However, MYB non-rearrangement was associated with a significantly higher rate of lymph node metastasis (75 % vs. 8.3 %, P = 0.027).</div></div><div><h3>Conclusion</h3><div>Investigating the heterogeneity and multimolecular characteristics of PACC based on different pathological types emerges as a potentially innovative strategy to pinpoint suitable candidates for targeted therapies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"201 ","pages":"Article 108414"},"PeriodicalIF":4.5000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500225000352","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Primary pulmonary adenoid cystic carcinoma (PACC) is a rare malignant tumor. Despite the growing sophistication of ACC research, scant studies have delved into the unique molecular alterations of ACC originating from the lung and the clinical features associations.
Method
Paraffin-embedded specimens of primary PACC tissues pathologically confirmed at the Affiliated Hospital of Qingdao University within the past decade were collected. We comprehensively evaluated the diversity of molecular alterations in PACC using immunohistochemistry (IHC) staining, fluorescence in-situ hybridization (FISH), and next-generation sequencing (NGS). Furthermore, the potential correlations between MYB rearrangement status and clinicopathological features were thoroughly analyzed.
Result
Twenty-one specimens of primary PACC were collected, including eighteen of the typical type and three of the solid-basaloid type. Fifteen (71.4 %) specimens exhibited positive MYB staining and MYB rearrangements. Notably, neither clinicopathological parameters nor MYB rearrangement predicted patients’ overall survival (OS). However, MYB non-rearrangement was associated with a significantly higher rate of lymph node metastasis (75 % vs. 8.3 %, P = 0.027).
Conclusion
Investigating the heterogeneity and multimolecular characteristics of PACC based on different pathological types emerges as a potentially innovative strategy to pinpoint suitable candidates for targeted therapies.
期刊介绍:
Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.